Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | ECE1 | P42892 | 7/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842487 | 0.92 | TACR1 (0.56) | ACECTSLCTSSCTSKECE1 | |
| SCHEMBL14941216 | 0.85 | ACE (0.68) | ACEECE1ALOX15LTA4H | |
| SCHEMBL29603940 | 0.85 | ACE (0.68) | ACEECE1ALOX15LTA4H | |
| SCHEMBL7422711 | 0.85 | ACE (0.68) | ACEECE1ALOX15LTA4H | |
| SCHEMBL9852029 | 0.84 | ACE (0.67) | ACEECE1ALOX15LTA4H | |
| SCHEMBL9852039 | 0.84 | ACE (0.67) | ACEECE1ALOX15LTA4H | |
| SCHEMBL9596908 | 0.84 | ACE (0.72) | ACEECE1ALOX15 | |
| SCHEMBL11855463 | 0.84 | ACE (0.72) | ACEECE1ALOX15 | |
| SCHEMBL5612810 | 0.84 | ACE (0.72) | ACEECE1ALOX15 | |
| SCHEMBL9596897 | 0.84 | ACE (0.72) | ACEECE1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ACE 3951/4885CTSL 1966/4885CTSS 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.